HIV/AIDS News

The CDC on Wednesday recommended that all sexually active adults and adolescent patients be informed about HIV PrEP.

On Wednesday, the White House marked World AIDS Day 2021 by releasing an updated national strategy to bolster the fight against HIV.

Globally, children and adolescents on ART lag adults in progress toward achieving viral suppression, according to new data published in The Lancet HIV ahead of World AIDS Day, which is Dec. 1.

A study published Tuesday on the eve of World AIDS Day described continuing inequities in HIV care among gay and bisexual men in the United States.

Gilead Sciences said the FDA has approved a new low-dose tablet form of its HIV drug Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to ART.

Anal HPV prevalence is high among men who have sex with men regardless of their HIV status, according to the results of a systematic review published in The Lancet HIV.

Subcutaneous lenacapavir in combination with an optimized background regimen led to sustained virologic suppression in 81% of heavily treated people with HIV at week 26, data from an ongoing phase 2/3 study showed.

Newly presented study findings reported higher adherence to two HIV prevention methods — oral PrEP and the dapivirine vaginal ring — among adolescent girls and young women in Africa than was shown in previous trials, researchers said.

Other than conversations about puberty, less than one-third of adolescents reported discussing sexual and reproductive health topics with their health care provider, according to a study published in Pediatrics.

Gilead Sciences submitted a new drug application to the FDA for the approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor that is given subcutaneously every 6 months.